• Find an Expert
  • Contact
  • SearchSearch icon
  • Menu
  • Help
  • Report an issue

Contact


Email

grace.kong@unimelb.edu.au

Credentials


Position
Honorary Conjoint Principal Fellow
The Sir Peter MacCallum Department of Oncology
ORCID

0000-0002-9269-3435

A/Prof Grace Kong

Honorary Conjoint Principal Fellow
The Sir Peter MacCallum Department of Oncology

56 Scholarly works
0 Projects

HIGHLIGHTS

  • 2026

    Journal article

    [177Lu]Lu-PSMA-617 in combination with pembrolizumab for treatment of metastatic castration resistant prostate cancer (PRINCE): a single-arm, phase 1b/2 study
    DOI: 10.1016/S1470-2045(26)00017-3
  • 2025

    Journal article

    Prognostic Value of Initial Imaging and PSA Change with [177Lu]Lu-PSMA-617 Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A ProsTIC Registry Analysis
    DOI: 10.2967/jnumed.125.270804
  • 2025

    Journal article

    Lutetium-177 [177Lu]Lu-PSMA-I&T plus radium-223 in patients with metastatic castration-resistant prostate cancer (AlphaBet): an interim analysis of the investigator-initiated, single-centre, single-arm, phase 1/2 trial
    DOI: 10.1016/S1470-2045(25)00559-5
  • 2025

    Journal article

    2386P A phase I/II trial of combined Radium-223 and Lutetium-177 PSMA-I&T in patients with metastatic castration-resistant prostate cancer (mCRPC): First analysis of the AlphaBet trial
    DOI: 10.1016/j.annonc.2025.08.3002
  • 2025

    Journal article

    First-in-human results of terbium-161 [161Tb]Tb-PSMA-I&T dual beta–Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET): a single-centre, single-arm, phase 1/2 study
    DOI: 10.1016/S1470-2045(25)00332-8
  • 2025

    Journal article

    Lutetium-177–PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial
    DOI: 10.1038/s41591-025-03704-9
  • 2025

    Journal article

    Approach to the Management of Gastrointestinal Manifestations in Patients With Phaeochromocytoma and Paraganglioma
    DOI: 10.1111/cen.15235
Grace Kong

RECENT SCHOLARLY WORKS

  • 2025

    Journal article

    Peptide receptor radionuclide therapy in malignant insulinoma
    DOI: 10.1530/ERC-25-0018
  • 2025

    Journal article

    First-in-human results of terbium-161[ 161 Tb]Tb-PSMA-I&T radioligand treatment in patients with metastatic castration-resistant prostate cancer (VIOLET): A single-centre, single-arm, phase I/II study.
    DOI: 10.1200/jco.2025.43.16_suppl.5010
  • 2025

    Journal article

    Therapy-Related Myeloid Neoplasms After [177Lu]Lu-PSMA Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A Case Series
    DOI: 10.2967/jnumed.124.268640

We acknowledge and pay respect to the Traditional Owners of the lands upon which our campuses are situated

Read about our commitment to reconciliation  

About us  

Careers at Melbourne  

Safety and respect  

Newsroom  

Contact  

Phone: 13 MELB ( 13 6352)

International: +61 3 9035 5511


Address:
The University of Melbourne
Grattan Street, Parkville,
Victoria, 3010, Australia


View all Campus locations  
facebookIconlinkedinIconinstagramIcontwitterIcon

Emergency information  |  Disclaimer and copyright  |  Accessibility  |  Privacy  |  VaxFACTS

CRICOS number: 00116K     ABN: 84 002 705 224